Stocklytics Platform
Asset logo for symbol MRKR
Marker Therapeutics
MRKR83
$5.45arrow_drop_up3.02%$0.16
High Growth
Penny Stock
Asset logo for symbol MRKR
MRKR83

$5.45

arrow_drop_up3.02%

Performance History

Chart placeholder
Key Stats
Open$5.35
Prev. Close$5.29
EPS-1.38
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$48.53M
PE Ratio-
LOWHIGH
Day Range5.21
5.51
52 Week Range2.40
9.68
Ratios
EPS-1.38

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Correlated Companies

Asset logo for symbol LLY
Eli Lilly & Co
LLY74
Price$804.62
Perf. (24h)
arrow_drop_down2.01%-$16.57
Market Cap$738.87B
Asset logo for symbol UNH
UnitedHealth Group
UNH71
Price$569.71
Perf. (24h)
arrow_drop_up1.79%$10.03
Market Cap$527.83B
Asset logo for symbol JNJ
Johnson & Johnson
JNJ62
Price$160.64
Perf. (24h)
arrow_drop_up0.62%$1.00
Market Cap$382.01B
Asset logo for symbol ABBV
AbbVie
ABBV62
Price$185.16
Perf. (24h)
arrow_drop_up1.64%$2.99
Market Cap$326.96B

About Marker Therapeutics (MRKR)

Marker Therapeutics Inc (MRKR) is a biotechnology company that focuses on the development and commercialization of innovative cell-based immunotherapies for the treatment of various cancers. The company's proprietary technology platform, known as MultiTAA, is designed to stimulate the body's immune system to recognize and destroy cancer cells. MRKR's approach is based on the principle of utilizing the patient's own immune system to target and eliminate cancer cells, potentially providing a more effective and less toxic treatment option compared to traditional therapies.
MRKR's lead product candidate, MT-401, is currently being evaluated in a Phase 2 clinical trial for the treatment of acute myeloid leukemia (AML) following hematopoietic stem cell transplantation. The trial aims to assess the safety and efficacy of MT-401 in this patient population, which has a high risk of relapse and poor outcomes. Preliminary data from the trial has shown promising results, with a significant reduction in the risk of relapse and prolonged survival observed in patients treated with MT-401 compared to historical controls.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Juan F. Vera M.D.
Headquarters
Houston
Employees
67
Exchange
NASDAQ
add Marker Therapeutics to watchlist

Keep an eye on Marker Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Marker Therapeutics 's (MRKR) price per share?
The current price per share for Marker Therapeutics (MRKR) is $5.45. The stock has seen a price change of $0.16 recently, indicating a 3.02% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Marker Therapeutics (MRKR)?
For Marker Therapeutics (MRKR), the 52-week high is $9.68, which is 77.61% from the current price. The 52-week low is $2.4, the current price is 127.08% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Marker Therapeutics (MRKR) a growth stock?
Marker Therapeutics (MRKR) has shown an average price growth of 0.41% over the past three years. It has received a score of 97 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Marker Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Marker Therapeutics (MRKR) stock price performance year to date (YTD)?
As of the latest data, Marker Therapeutics (MRKR) has a year-to-date price change of -0.18%. Over the past month, the stock has experienced a price change of 17.46%. Over the last three months, the change has been 24.86%. Over the past six months, the figure is 26.16%. Looking at a longer horizon, the five-year price change stands at -89.76%.
help
Is Marker Therapeutics (MRKR) a profitable company?
Marker Therapeutics (MRKR) has a net income of -$14.05M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -204.9% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $3.31M, although specific revenue growth data is currently not available. Operating income is noted at -$14.58M. Furthermore, the EBITDA is $0.
help
What is the market capitalization of Marker Therapeutics (MRKR)?
Marker Therapeutics (MRKR) has a market capitalization of $48.53M. The average daily trading volume is 26.58K, indicating the stock's liquidity and investor engagement.

News

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
EARNINGS RELEASES AND OPERATING RESULTS
HEALTH
5/15/2024

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 
HEALTH
PRODUCT / SERVICES ANNOUNCEMENT
CALENDAR OF EVENTS
4/8/2024

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
EARNINGS RELEASES AND OPERATING RESULTS
3/25/2024

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
CALENDAR OF EVENTS
3/22/2024

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
GOVERNMENT NEWS
HEALTH
PRODUCT / SERVICES ANNOUNCEMENT
1/22/2024

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
PRODUCT / SERVICES ANNOUNCEMENT
1/8/2024

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level